PRTA•benzinga•
Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits
Summary
Prothena and Roche report Phase 2b PADOVA results on prasinezumab in Parkinson's, showing promising trends and nominal significance in key analyses.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 19, 2024 by benzinga